WEBSITE BSE:512217 NSE: PRISM MEDI Inc. Year: 2002 Industry: Trading My Bucket: Add Stock
Last updated: 11:29
No Notes Added Yet
Prism Medico and Pharmacy Ltd. is an Indian public limited company incorporated on 21 February 1985. It is headquartered in Kala Amb, Sirmaur District, Himachal Pradesh and is listed on the Bombay Stock Exchange (BSE). The company’s authorised capital is ₹10 crore, with a paid-up share capital of approximately ₹6.06 crore, reflecting its modest size as a micro/small-cap listed enterprise. Originally, the company was incorporated under the name Woolite Mercantile Company Limited and later changed its name to Prism Medico and Pharmacy Ltd....Read More
Prism Medico and Pharmacy Ltd. is an Indian public limited company incorporated on 21 February 1985. It is headquartered in Kala Amb, Sirmaur District, Himachal Pradesh and is listed on the Bombay Stock Exchange (BSE). The company’s authorised capital is ₹10 crore, with a paid-up share capital of approximately ₹6.06 crore, reflecting its modest size as a micro/small-cap listed enterprise. Originally, the company was incorporated under the name Woolite Mercantile Company Limited and later changed its name to Prism Medico and Pharmacy Ltd. in 2012 to align with its evolving business focus. Prism’s corporate activities formally allow it to act as a manufacturer, buyer, seller, dealer, exporter, importer, trader, wholesaler, retailer, supplier, agent, stockist, processor, and distributor of a broad range of chemical and pharmaceutical products, including drugs, medicines, antibiotics, cosmetics, soaps, oils, dyes, pesticides, and related items. Over the years, Prism Medico and Pharmacy has engaged primarily in trading and distribution of pharmaceutical and allied products. In more recent times, it has also operated in segments that include agriculture-related products such as straw, fodder, animal and poultry feed, cattle feed, aqua feed, herbal extracts, ayurvedic and organic foods, juices, nutrients, and FMCG items. These diversified trading activities have formed the core of its revenue in recent reporting periods. Financial performance has been modest and uneven. In recent fiscal years, the company reported limited total revenue from operations, with some periods of small profits and occasional losses. This reflects the challenges of scaling its business and operating within competitive trading and distribution markets. The company’s share price and market capitalisation reflect its small size and position in the stock market. Prism Medico and Pharmacy is classified as a small-cap listed company, with its share price exhibiting volatility influenced by broader market trends rather than consistent earnings growth. Management and governance are overseen by a board of directors, including a whole-time director and additional directors responsible for strategic oversight and regulatory compliance. The company regularly submits financial results, annual reports, and disclosures required for a listed entity under Indian securities regulations. In summary, Prism Medico and Pharmacy Ltd. is a long-established but modestly scaled Indian company engaged primarily in wholesale and trading operations spanning pharmaceuticals, chemicals, and agricultural products. While its financial performance has been uneven and revenues relatively low in recent years, the company maintains its listed status and continues to pursue trading and distribution activities within its permitted corporate scope. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹42 Cr.
Stock P/E -863.4
P/B 1.8
Current Price ₹31
Book Value ₹ 17.1
Face Value 10
52W High ₹34.5
Dividend Yield 0%
52W Low ₹ 12.5
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 |
| Total Expenditure | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Operating Profit | -0 | 0 | -0 | -0 | 0 | -0 | 0 | 1 | -0 | -0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | 0 | -0 | -0 | 0 | -0 | 0 | 1 | -0 | -0 |
| Provision for Tax | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 |
| Profit After Tax | -0 | 0 | -0 | -0 | 0 | -0 | 0 | 1 | -0 | -0 |
| Adjustments | 0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -0 | 0 | -0 | -0 | 0 | -0 | 0 | 1 | -0 | -0 |
| Adjusted Earnings Per Share | -0.1 | 0.3 | -0.1 | -0.1 | 0 | -0 | 0.1 | 1.1 | -0.1 | -0 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 0 | 0 | 21 | 36 | 27 | 17 | 8 | 1 | 3 | 1 | 3 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 0 | 0 | 21 | 37 | 27 | 17 | 8 | 1 | 3 | 1 | 3 |
| Total Expenditure | 0 | 0 | 0 | 21 | 36 | 27 | 17 | 9 | 1 | 3 | 1 | 2 |
| Operating Profit | -0 | 0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | 1 |
| Provision for Tax | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 |
| Profit After Tax | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | 1 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | 1 |
| Adjusted Earnings Per Share | -0 | -0 | -0.4 | -0 | 0.6 | -0.1 | -0.2 | -0.6 | -0.1 | -0 | -0.1 | 1.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -67% | -50% | -48% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 126% | 3% | 25% | 10% |
| ROE Average | -0% | -0% | -1% | -1% |
| ROCE Average | -0% | -0% | -1% | -1% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 2 | 2 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 15 | 15 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Total Current Liabilities | 0 | 0 | 0 | 0 | 4 | 9 | 9 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2 | 2 | 13 | 13 | 17 | 22 | 21 | 12 | 15 | 15 | 15 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 10 | 11 | 10 | 2 | 2 | 0 | 0 | 0 | 0 |
| Total Current Assets | 2 | 2 | 3 | 2 | 7 | 20 | 19 | 12 | 15 | 15 | 15 |
| Total Assets | 2 | 2 | 13 | 13 | 17 | 22 | 21 | 12 | 15 | 15 | 15 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 0 | 0 | -1 | 0 | -1 | -4 | -0 | -2 | 3 | -0 | -0 |
| Cash Flow from Investing Activities | -0 | 0 | 0 | 0 | 1 | 4 | 0 | 2 | -3 | 0 | 0 |
| Cash Flow from Financing Activities | 0 | 0 | 1 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net Cash Inflow / Outflow | 0 | 1 | 1 | 0 | 0 | -0 | -0 | -0 | 0 | -0 | -0 |
| Closing Cash & Cash Equivalent | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -0.05 | -0.04 | -0.37 | -0.03 | 0.61 | -0.08 | -0.21 | -0.61 | -0.13 | -0.04 | -0.08 |
| CEPS(Rs) | -0 | 0.01 | -0.35 | 0.04 | 0.65 | -0.05 | -0.19 | -0.6 | -0.12 | -0.03 | -0.07 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 8.21 | 8.17 | 21.11 | 21.08 | 21.69 | 21.53 | 21.32 | 20.71 | 25.01 | 24.97 | 24.89 |
| Core EBITDA Margin(%) | 0 | -74.24 | -317.95 | 0.44 | 0.28 | -0.19 | -0.97 | -5.8 | -7.63 | -4.71 | -12.09 |
| EBIT Margin(%) | 0 | -9.74 | -258.97 | 0.22 | 0.81 | -0.25 | -1.04 | -5.9 | -8.02 | -0.71 | -10.14 |
| Pre Tax Margin(%) | 0 | -9.76 | -259.1 | 0.22 | 0.81 | -0.25 | -1.05 | -5.91 | -8.04 | -0.96 | -10.41 |
| PAT Margin (%) | 0 | -9.76 | -261.25 | -0.09 | 1.02 | -0.19 | -0.78 | -4.38 | -6 | -0.73 | -7.71 |
| Cash Profit Margin (%) | 0 | 1.28 | -243.32 | 0.12 | 1.09 | -0.12 | -0.7 | -4.28 | -5.49 | -0.55 | -7.04 |
| ROA(%) | -0.54 | -0.47 | -3.05 | -0.15 | 2.47 | -0.26 | -0.6 | -2.18 | -0.55 | -0.14 | -0.32 |
| ROE(%) | -0.55 | -0.51 | -3.15 | -0.15 | 2.85 | -0.38 | -1 | -2.9 | -0.55 | -0.14 | -0.32 |
| ROCE(%) | -0.55 | -0.49 | -3.11 | 0.37 | 2.26 | -0.52 | -1.35 | -3.91 | -0.74 | -0.14 | -0.42 |
| Receivable days | 0 | 365 | 0 | 0 | 37.78 | 149.95 | 346.74 | 397.56 | 1384.74 | 527.23 | 2100.76 |
| Inventory Days | 0 | 0 | 3314.34 | 14.59 | 9.28 | 6.85 | 53.28 | 251.09 | 1944.81 | 844.82 | 3910.85 |
| Payable days | 0 | 365 | 0 | 0 | 36.99 | 82.41 | 184.95 | 0 | 0 | 4.39 | 0 |
| PER(x) | 0 | 0 | 0 | 0 | 60.73 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 2.2 | 0 | 1.83 | 1.13 | 1.71 | 0.58 | 0.55 | 0.37 | 1.15 | 1.09 | 0.47 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0 | 17.31 | 253.6 | 0.69 | 0.61 | 0.28 | 0.42 | 0.54 | 13.59 | 5.63 | 11.14 |
| EV/Core EBITDA(x) | -5290.83 | 1329.64 | -105.21 | 157.71 | 69.71 | -148.01 | -42.94 | -9.32 | -181.15 | -1054.96 | -117.54 |
| Net Sales Growth(%) | 0 | 0 | 2.31 | 0 | 73.23 | -25.93 | -37.66 | -49.63 | -84.95 | 130.2 | -78.4 |
| EBIT Growth(%) | 81.62 | 8.21 | -2620.22 | 120.79 | 526.61 | -123.13 | -157.8 | -184.9 | 79.56 | 79.49 | -206.7 |
| PAT Growth(%) | 82.16 | 8.23 | -2638.45 | 91.68 | 2053.23 | -113.6 | -158.7 | -184.5 | 79.37 | 71.95 | -127.57 |
| EPS Growth(%) | 82.15 | 8.15 | -798.8 | 91.68 | 2052.88 | -113.61 | -158.62 | -184.51 | 79.38 | 71.94 | -127.48 |
| Debt/Equity(x) | 0.01 | 0.04 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 36.77 | 8.21 | 11.58 | 17.93 | 1.8 | 2.29 | 2.26 | 708.22 | 65.35 | 147.68 | 32.43 |
| Quick Ratio(x) | 36.77 | 8.21 | 8.42 | 7.85 | 1.55 | 2.29 | 1.7 | 319.61 | 36.13 | 80.97 | 18.08 |
| Interest Cover(x) | -438.02 | -481.55 | -2024.32 | 249.11 | 1296.17 | -272.12 | -709.78 | -1083.14 | -339.67 | -2.94 | -37.71 |
| Total Debt/Mcap(x) | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25.49 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 74.51 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.61 | 0.61 | 0.61 | 0.61 | 0.61 | 0.61 | 0.61 | 0.61 | 0.61 | 0.61 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
